Price
$28.62+11.45%Social Signal Score
Analyst Ratings
18 analystsRevenue
$9.00MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Terry J. Rosen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 601
- Beta
- 0.81
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -1.06
Financials
Revenue
$9.00M+5421.5%Net Income
$-128.00MEBITDA
$-123.00MFree Cash Flow
$-88.00MEPS (diluted)
$-1.00Shares Outstanding (diluted)
127.40M+418.8%Operating Expenses
$140.00MCash & Debt
$630.00MReturn of Capital
$0.00Revenue by Segment (annual)
$253.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $247.00M | $-353.00M | $-3.29 |
| 2024 | $258.00M | $-283.00M | $-3.14 |
| 2023 | $117.00M | $-307.00M | $-4.15 |
| 2022 | $112.00M | $-267.00M | $-3.71 |
| 2021 | $383.00M | $53.00M | $0.76 |
| 2020 | $78.00M | $-123.00M | $-2.24 |
| 2019 | $15.00M | $-84.71M | $-1.93 |
| 2018 | $8.35M | $-49.59M | $-1.43 |
| 2017 | $1.41M | $-53.08M | $-2.16 |
| 2016 | $0.00 | $-17.97M | $-0.73 |
Valuation
RCUShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-72.73%Social Signal Score
Mentions (12)
- Newsbusinesswire.com·27d ago·Negative
Arcus Biosciences Announces New Employment Inducement Grants HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 10,650 shares of the Company's common stock at an ex…
View source ↗ - Newsbusinesswire.com·31d ago·Neutral
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock at a price to the public of $17.50 per share. Gross proceeds to Arcus Bioscienc…
View source ↗ - Newsbusinesswire.com·32d ago·Negative
Arcus Biosciences Announces Commencement of Public Offering of Common Stock HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that it has commenced an underwritten public offering of its common stock. All of the shares of common stock are being offered by Arcus Biosciences. In addition, Arcu…
View source ↗ - Newsseekingalpha.com·32d ago·Neutral
…ead Arcus Biosciences presented promising ARC-20 platform data for casdatifan across first-line, second-line, and late-line clear cell renal cell carcinoma settings. RCUS's casdatifan combinations showed superior or competitive PFS and response rates versus historical benchmarks, with manageable safety profiles and broad potential across treatment lines. Valuation is rich at 22.5x trailing and 37.9x forward sales, reflecting high pipeline expectations and leaving RCUS vulnerable to clinical setb…
View source ↗ - Newsseekingalpha.com·33d ago·Positive
Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript
View source ↗ - Newsbusinesswire.com·44d ago·Negative
Arcus Biosciences Announces New Employment Inducement Grants HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, today announced that the Compensation Committee of the Company's Board of Directors granted 2 new employees options to purchase a total of 9,150 shares of the Company's common stock at an e…
View source ↗ - Newsbusinesswire.com·59d ago·Negative
Arcus Biosciences Announces New Employment Inducement Grants HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 21,200 shares of the Company's common stock at …
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsbusinesswire.com·74d ago·Neutral
Arcus Biosciences Announces New Employment Inducement Grants HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 26,350 shares of the Company's common s…
View source ↗ - Newsseekingalpha.com·74d ago·Positive
Arcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Arcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsbusinesswire.com·103d ago·Neutral
Arcus Biosciences Announces New Employment Inducement Grants HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 2,850 shares of the Company's common st
View source ↗ - Newsmarketbeat.com·105d ago·Neutral
Arcus Biosciences Q2 Earnings Call Highlights Arcus Biosciences NYSE: RCUS outlined plans to expand development of its casdatifan cancer program across multiple lines of clear cell renal cell carcinoma, or ccRCC, while reporting second-quarter financial results and updates on its pancreatic cancer and immunology pipelines.
View source ↗
Earnings
Wed, Feb 24(in 3 months)
Consensus estimate $-0.89 per share
Typical surprise +4.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-1.00 vs $-0.89miss
- Wed, Aug 5$-0.72 vs $-0.89beat
- Tue, May 5$-1.02 vs $-0.92miss
- Wed, Feb 25$-0.89 vs $-1.11beat
- Tue, Oct 28$-1.27 vs $-1.33beat
- Wed, Aug 6$-0.08 vs $-1.14beat
Estimates and results for RCUS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RCUS officers and directors.
- Bought
- —
- Sold
- $14.4m
0 trades
46 trades
- Azoy Alexandersold
- Jaen Juan C.sold
- Jaen Juan C.sold
- Jaen Juan C.sold
- Jaen Juan C.sold
- Jaen Juan C.sold
- Jaen Juan C.sold
- Jaen Juan C.sold
54 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RCUS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
